ReviewWorld journal of gastroenterology2014
Therapeutic drug monitoring in patients with inflammatory bowel disease.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- The aspiration of precision glucocorticoid pharmacotherapy in immune-mediated diseases: where do we stand in integrating pharmacogenomics and biomarkers for individualized treatment?Frontiers in immunology · 2026Review
- Analysis of Azathioprine Metabolites in Autoimmune Hepatitis Patient Blood-Method Development and Validation.International journal of molecular sciences · 2024Article
- Crohn's disease and clinical management today: How it does?World journal of methodology · 2023Review
- Analysis of the Immunogenicity from Abatacept-Treated Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials.ACR open rheumatology · 2022Article
- Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2021Article
- Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.Journal of clinical gastroenterology · 2021Review
- Thiopurine-induced Myelosuppression with Severe Sepsis in a Patient with Crohn's Disease: A Case Report.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Optimizing Thiopurine Therapy with a Xanthine Oxidase Inhibitor in Patients with Systemic Autoimmune Diseases: A Single-Centre Experience.The Canadian journal of hospital pharmacy · 2021Article
- Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents.Frontiers in pharmacology · 2021Article
- ThiopurineTherapeutic advances in gastroenterology · 2020Article
- Echinochrome A Reduces Colitis in Mice and Induces In Vitro Generation of Regulatory Immune Cells.Marine drugs · 2019Article
- Ulcerative colitis.Lancet (London, England) · 2017Review
- Insights on the use of biosimilars in the treatment of inflammatory bowel disease.World journal of gastroenterology · 2017Review
- Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.Journal of clinical and experimental hepatology · 2017Review
- Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of ColitisFrontiers in immunology · 2017Article
- Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.The AAPS journal · 2017Article
- Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies.Pharmacogenomics and personalized medicine · 2017Review
- Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study.Inflammatory bowel diseases · 2016Article
- The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.Digestive diseases and sciences · 2016Article
- A Personalized Approach to Managing Inflammatory Bowel Disease.Gastroenterology & hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.